US Corporate Distress Financial Stress SEC Filings — June 24, 2026

USA Corporate Distress & Bankruptcy

By Gunpowder Editorial ·

50 high priority 50 total filings analysed

Executive Summary

The 50 filings reveal a bifurcated corporate landscape on June 24, 2026, with acute distress signals concentrated in micro-cap and pre-revenue biotech/tech companies, while larger, established firms engage in routine capital management. The most critical developments include the imminent delisting of Aditxt (ADTX) and the high-risk reverse split at SRx Health Solutions (SRXH), both representing terminal distress.

A significant theme is the aggressive use of reverse stock splits and dilutive financing by cash-strapped companies to maintain exchange listings, a pattern that has historically failed. Conversely, several companies are executing strategic pivots: Comstock Inc. sold legacy mining assets for $45M+ to focus on renewable metals, and Hyperscale Data secured a $1.2B+ AI compute contract, signaling a shift from crypto to AI infrastructure. The data also shows a wave of SPAC activity (Churchill Capital XI, Gores Holdings XI, Wilco 63) targeting AI and robotics, indicating strong market appetite for exposure to these themes. Period-over-period data, where available, shows revenue growth at Worksport (+47.9% YoY) and margin improvement, but this is overshadowed by the company's cash flow negativity. The overarching theme is a 'survival of the fittest' dynamic where companies with clear strategic direction and access to capital are thriving, while those with weak fundamentals and repeated compliance failures are facing extinction.

Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →

Filing types in this digest: 8-K

Tracking the trend? Catch up on the prior US Corporate Distress Financial Stress SEC Filings digest from June 23, 2026.

Investment Signals (12)

  • Aditxt (ADTX) (BEARISH)

    Nasdaq has denied continued listing, with trading suspended effective June 25, 2026. The company has a negative equity of -$35.2M and has completed seven reverse stock splits, all of which failed to maintain compliance. This is a terminal signal for equity holders

  • SRx Health Solutions (SRXH) (BEARISH)

    Received a delisting notice from NYSE American after stock price fell below $0.10. Trading is halted pending a 1-for-60 reverse split. The extreme ratio indicates a desperate attempt to maintain listing, with high probability of failure

  • Hyperscale Data (GPUS-PD) (BULLISH)

    Signed a 10-year MSA for 20 MW of AI compute capacity, expected to generate over $1.2B in revenue. This marks a successful pivot from Bitcoin mining to AI infrastructure, with a clear path to monetizing its 300 MW Michigan campus

  • Sold legacy mining assets for $45M+, reducing annual costs by $1.5M and providing a cash injection of $20M. This strategic pivot to renewable metals removes a legacy drag on the balance sheet

  • Q1 2026 net sales grew 47.9% YoY and gross profit surged 115.5% YoY, with gross margins improving to 26%. However, the company is not yet cash-flow positive and required a premium-priced ($1.20 vs $0.60 market) $250K investment, signaling ongoing capital needs

  • Announced a ~$19.5M private placement that is entirely a debt-for-equity swap, not new cash. This dilutes existing shareholders by over 12 million shares and signals the company is unable to raise new capital, relying on converting debt to equity

  • Issued 259 million shares at $0.021 per share to raise $5.45M, causing massive dilution. The company is pivoting to AI but the extreme dilution suggests a high burn rate and desperate capital raising

  • Raised $100M in an underwritten offering with participation from Eli Lilly, a strong vote of confidence from a major pharma partner. Proceeds will fund key pipeline programs (ABS-201)

  • Selectis Health (GBCS) (BULLISH)

    Agreed to be acquired by Black Pearl Equities for $5.75/share in cash, providing a clear exit for shareholders. The deal has no financing contingency and is expected to close in Q3 2026

  • Settled PFAS-related claims with the EPA for $22.5M civil penalty and $90M in mitigation projects. While costly, this provides long-sought regulatory clarity and removes a major overhang, supporting the 'Pathway to Thrive' strategy

  • Implementing a 1-for-35 reverse stock split, a strong indicator of distress as the company fights to maintain its listing. This follows a pattern of similar actions by cash-strapped micro-caps

  • FDA cleared the company to resume its Phase 2 KOURAGE trial after a voluntary pause, with no clinical hold. The agency also has no comments on the protocol amendment, de-risking the program. Expects FDA feedback on a pivotal program in Q3 2026

Risk Flags (10)

  • Aditxt (ADTX) / Delisting [CRITICAL RISK]

    Final delisting from Nasdaq effective June 25, 2026. The company has a negative equity of -$35.2M, no revenue-generating products, and has failed seven reverse stock splits. Equity is essentially worthless

  • SRx Health Solutions (SRXH) / Delisting [HIGH RISK]

    Trading halted on NYSE American with a 1-for-60 reverse split planned. The stock was below $0.10, and the extreme split ratio is unlikely to restore long-term compliance. High risk of OTC trading

  • The $19.5M private placement is a debt-for-equity swap, providing no new cash. This signals the company cannot attract new capital and is converting debt to equity, which is a classic precursor to financial distress

  • GD Culture Group (GDC) / Dilution [HIGH RISK]

    Issued 259 million shares (a massive increase in share count) for only $5.45M. This extreme dilution suggests a high cash burn rate and limited access to capital markets, putting the company's survival at risk

  • A 1-for-35 reverse split is a strong distress signal. The company is likely struggling to maintain its Nasdaq listing, and such splits often precede further price declines

  • Despite strong revenue growth (+47.9% YoY), the company is not cash-flow positive and required a premium-priced $250K investment. The target of reaching cash-flow positivity within 2026 is ambitious and uncertain

  • Consolidated Water Co. (CWCO) / Revenue Headwind [MODERATE RISK]

    The new 25-year license in the Cayman Islands introduces a lower rate structure that would have reduced revenues by $2.1M in 2024 and $1.9M in 2025. This is a material and permanent headwind to earnings

  • Compass Diversified (CODI) / Bankruptcy Exposure [MODERATE RISK]

    The company is entangled in the Chapter 11 proceedings of Lugano Diamonds. While a settlement has been reached, it is subject to court approval, and the timing and amount of recovery are uncertain

  • Passage Bio shareholders will own only ~7% of the combined company and receive non-transferable CVRs tied to uncertain pediatric gene therapy milestones. This is effectively a near-total loss of value for current shareholders

  • Indaptus Therapeutics (INDP) / Dilution [MODERATE RISK]

    Issued 20 million shares at $0.60 per share, representing less than 20% of outstanding stock. While not as extreme as others, this is a dilutive event for a pre-revenue biotech

Opportunities (10)

  • Hyperscale Data (GPUS-PD) / AI Compute Catalyst (OPPORTUNITY)

    The 10-year, $1.2B+ MSA with a neocloud provider provides a clear, long-term revenue stream. The option to expand to 52 MW could increase the contract value to $3.0B+. This is a transformative deal that validates the pivot from Bitcoin mining

  • The $45M+ sale of legacy mining assets provides a clean balance sheet and $20M in cash to focus on renewable metals. The elimination of $1.5M in annual costs improves the path to profitability

  • The $100M offering with participation from Eli Lilly is a strong validation of the company's AI drug discovery platform. The proceeds will fund key pipeline programs, and the partnership with a top pharma company provides a significant competitive advantage

  • Selectis Health (GBCS) / Takeover Arbitrage (OPPORTUNITY)

    The $5.75/share all-cash acquisition by Black Pearl Equities provides a clear, near-term return. The deal has no financing contingency, and the tender offer is expected within 10 business days, offering a low-risk arbitrage opportunity

  • CalciMedica (CALC) / FDA De-Risking (OPPORTUNITY)

    The FDA's clearance to resume the Phase 2 KOURAGE trial with no comments on the protocol is a major de-risking event. The upcoming FDA feedback on a pivotal program for acute pancreatitis in Q3 2026 is a key catalyst

  • The PFAS settlement, while costly, removes a significant regulatory overhang. The company's 'Pathway to Thrive' strategy can now proceed with more certainty, and the stock may re-rate as this risk is priced out

  • Churchill Capital XI (CCXI) / Agility Robotics SPAC (OPPORTUNITY)

    The $2.5B valuation for Agility Robotics, the only U.S. publicly listed pure-play humanoid company, offers exposure to a high-growth AI theme. The $620M in gross proceeds provides a strong cash position for growth

  • The $250M financing agreement with Hannover Re provides a significant capital source to fund sales and marketing growth through 2028. This removes a key funding overhang and supports the company's growth strategy

  • Parks America (PRKA) / Improved Liquidity (OPPORTUNITY)

    The $2.33M refinancing removes a $2.5M cash collateral reserve requirement, significantly improving liquidity. The fixed interest rate swap (6.99%) provides certainty on interest costs

  • FuelCell Energy (FCEL) / Data Center Demand (OPPORTUNITY)

    The strategic agreement with Fit Energy for up to 380 MW of on-site power for data centers is a major validation of the technology. The immediate deposit for an initial 30 MW delivery provides near-term revenue visibility

Sector Themes (6)

  • Micro-Cap Distress Spiral

    A clear pattern of distress is evident among micro-cap companies (Aditxt, SRx Health, Nuwellis, GD Culture Group). They are using reverse stock splits and highly dilutive financings as a last resort to maintain listings, but these actions historically fail to address underlying business problems. This creates a 'death spiral' where repeated dilution destroys shareholder value.

  • AI Infrastructure Gold Rush

    Companies pivoting to AI infrastructure are attracting significant capital and strategic deals. Hyperscale Data's $1.2B contract and FuelCell Energy's 380 MW agreement with Fit Energy highlight the immense demand for power and compute capacity to support AI workloads. This is a multi-year secular trend.

  • Biotech Cash Burn and Financing

    Pre-revenue biotechs (Absci, uniQure, Indaptus, Passage Bio) continue to rely on dilutive equity offerings to fund R&D. The participation of strategic investors like Eli Lilly in Absci's offering is a positive signal, but the overall theme is one of high cash burn and reliance on capital markets.

  • SPAC Resurgence with AI/Robotics Focus

    The market is seeing a wave of new SPAC IPOs (Churchill Capital XI, Gores Holdings XI, Wilco 63) and de-SPAC transactions (Agility Robotics). The common thread is a focus on AI, automation, and robotics, indicating strong investor appetite for these themes via the SPAC structure.

  • Regulatory Clarity as a Catalyst

    For companies like Chemours (PFAS settlement) and Consolidated Water (new 25-year license), the resolution of long-standing regulatory uncertainty is a significant event. While the terms may be costly, the removal of the overhang allows management to focus on operations and can lead to a re-rating of the stock.

  • Activist Engagement and Board Refreshment

    The filings show two instances of activist engagement (Oportun Financial with Bradley Radoff, CEA Industries with YZi Labs) leading to board changes and standstill agreements. This theme suggests that underperforming companies are being pressured to improve governance and strategy.

Watch List (8)

  • Aditxt (ADTX)
    👁

    Trading suspended June 25, 2026. Watch for any appeal or move to OTC markets. The stock is likely to be worthless, but the company's next move (e.g., bankruptcy filing) is critical to monitor.

  • SRx Health Solutions (SRXH)
    👁

    The 1-for-60 reverse split is effective July 6, 2026. Watch for the stock's performance post-split. If it fails to hold above $0.10, delisting is imminent.

  • CalciMedica (CALC)
    👁

    Expects FDA feedback on a potential pivotal program for Auxora in acute pancreatitis in Q3 2026. This is a major catalyst that could significantly de-risk the program and drive the stock.

  • Selectis Health (GBCS)
    👁

    The tender offer from Black Pearl Equities is expected to commence within ten business days of June 23, 2026. Watch for the launch of the tender offer and the timeline to close in Q3 2026.

  • Hyperscale Data (GPUS-PD)
    👁

    Watch for progress on the 20 MW AI compute deployment and any exercise of the option to expand to 52 MW. The company's ability to secure financing for the $100M-$120M retrofit is a key risk to monitor.

  • The company targets reaching operational cash-flow positivity within 2026 and a quarterly revenue goal of $9M. Watch upcoming quarterly reports for progress against these targets.

  • The PFAS Consent Decree requires court approval. Watch for the court's decision and the company's execution of the $90M mitigation projects over 15 years. The stock's reaction to the removal of the overhang is key.

  • CEA Industries (BNC)
    👁

    The annual stockholder meeting is set for July 22, 2026. Watch for the appointment of a permanent CEO and any updates on the BNB treasury strategy.

Filing Analyses (50)
Worksport Ltd 8-K mixed materiality 8/10

24-06-2026

Worksport Ltd. announced a premium-priced direct investment of $250,000 at $1.20 per share, representing a 100% premium to its recent trading price of $0.5983, with the investor expressing interest in up to $10 million in additional financing. The company also reported Q1 2026 net sales of $3.3 million (up 47.9% YoY) and gross profit of $854,000 (up 115.5% YoY), with gross margin improving to 26%. However, the company remains not yet cash-flow positive and targets reaching operational cash-flow positivity within 2026, with a quarterly revenue goal of $9M and 35% gross margins.

  • · The investment was completed through a registered direct offering under Worksport's effective shelf registration statement on Form S-3.
  • · The warrants are exercisable at $1.50 per share.
  • · D. Boral Capital LLC acted as exclusive placement agent.
  • · Worksport recently announced a distribution relationship with Tri-State Enterprises, projected to become a seven-figure annual account.
  • · Terravis Energy secured a newly issued U.S. patent for its ZeroFrost heat-pump technology.
  • · The company's shares were trading at $0.5983 prior to the announcement.
SRx Health Solutions, Inc. 8-K negative materiality 9/10

24-06-2026

SRx Global, Inc. (SRXH) disclosed it received a delisting notice from NYSE American on March 23, 2026, for failing to meet continued listing standards due to its stock price closing below $0.10 on June 23, 2026, and trading has been halted. To regain compliance, the company announced a 1-for-60 reverse stock split, effective July 6, 2026, authorized by the board and majority shareholders within a range of 15-to-1 to 85-to-1. The company faces significant risk of delisting if the reverse split does not raise the stock price sufficiently, and trading remains halted until the split is effectuated.

  • · Trading of SRXH common stock has been halted by NYSE American and will remain halted until the reverse split is effectuated.
  • · The reverse split will not change the par value of the common stock ($0.001).
  • · No fractional shares will be issued; holders entitled to a fractional share will receive one whole share.
  • · Stockholders holding shares in brokerage accounts need not take any action to exchange shares.
  • · The company's transfer agent, Equity Stock Transfer LLC, will handle the exchange for certificate holders.
Comstock Inc. 8-K mixed materiality 9/10

24-06-2026

Comstock Inc. sold 100% of its legacy mining assets to Mackay Precious Metals Inc. for over $45 million, including $20 million in cash at closing, 2 million shares of Mackay Gold & Silver Corp. valued at over $3.5 million, a secured second-tranche cash payment of $7 million due within 18 months, a retained 1.5% NSR royalty, and a contingent future payment of $10 million. The transaction is expected to reduce ongoing costs by over $1.5 million annually and marks a strategic shift from a junior mining company to a renewable metals and materials company. However, the contingent payment is subject to uncertain milestones, and the second-tranche payment may be partially satisfied with shares, introducing dilution risk.

  • · The transaction follows a prior lease of Comstock's Northern Targets starting June 2023 and their purchase in December 2024 for $3.85 million.
  • · Over the life of all transactions with Mackay, Comstock received approximately $8 million including prior lease payments and reimbursed expenses.
  • · Mackay may elect to satisfy up to $2 million of the second-tranche payment through additional shares, subject to pricing thresholds.
  • · The contingent $10 million payment is triggered if Mackay decides to construct a mine or undergoes a change-of-control transaction with aggregate consideration of at least $500 million within seven years.
  • · If the contingent payment does not occur, the NSR buy-out price doubles from $3.5 million to $7 million.
  • · All reclamation obligations, liabilities, and associated surety bond deposits and collateral are assumed by the sold entities.
  • · Comstock retains a 1.5% NSR royalty on all valuable minerals extracted from the properties.
SELECTIS HEALTH, INC. 8-K positive materiality 9/10

24-06-2026

Selectis Health, Inc. (OTCQB: GBCS) has entered into a definitive agreement to be acquired by affiliates of Black Pearl Equities for $5.75 per share in cash, representing a meaningful premium to stockholders. The transaction, unanimously approved by Selectis's Board, is expected to close in Q3 2026, subject to conditions including tender of at least 70% of outstanding shares and regulatory approvals, with no financing contingency. The announcement highlights a positive outlook for stockholders, though the deal faces customary risks and uncertainties.

  • · The transaction is structured as a cash tender offer followed by a short-form merger under Utah law, with no stockholder vote required after the Offer.
  • · The Offer is expected to commence within ten business days of June 23, 2026.
  • · Selectis currently operates eight properties in Arkansas and Oklahoma, providing skilled nursing, assisted living, and independent living services.
  • · Reimbursement sources include Medicare, Medicaid, and private pay.
  • · The transaction is not subject to any financing contingencies.
  • · Selectis's Board unanimously approved the Merger Agreement and determined it is fair to stockholders.
Nuwellis, Inc. 8-K negative materiality 8/10

24-06-2026

Nuwellis, Inc. filed an 8-K on June 24, 2026, announcing a reverse stock split at a ratio of 1-for-35, effective June 25, 2026 at 5:00 p.m. ET. The amendment increases authorized shares from an unspecified prior amount to 140,000,000 (100,000,000 Common and 40,000,000 Preferred), all with $0.0001 par value. No fractional shares will be issued; holders will receive cash in lieu thereof based on the closing price on the last trading day before the effective time.

  • · The reverse stock split is effective June 25, 2026 at 5:00 p.m. ET.
  • · No fractional shares will be issued; cash payment will be based on the closing price on the last trading day before the effective time.
  • · The amendment was approved by the Board of Directors and stockholders in accordance with Section 242 of the DGCL.
FUELCELL ENERGY INC 8-K positive materiality 8/10

24-06-2026

FuelCell Energy and Fit Energy announced a strategic agreement for up to 380 MW of clean baseload on-site power for data centers using FuelCell Energy's fuel cell technology. The agreement includes an immediate deposit for an initial 30 MW delivery expected to begin later this year, with warrants tied to future deployment milestones. This partnership validates FuelCell Energy's decision to scale operations to 500 MW and positions it to serve the growing AI infrastructure power demand.

  • · Fit Energy will be eligible to receive warrants tied to future deployment milestones of up to 380 MW.
  • · Canaccord Genuity served as financial advisor to FuelCell Energy on certain aspects of this transaction.
  • · Fit Energy is focused on long-term ownership of generation assets for the digital economy.
  • · FuelCell Energy's global fuel cell deployments approach one gigawatt.
CalciMedica, Inc. 8-K neutral materiality 7/10

24-06-2026

CalciMedica, Inc. entered into a First Amendment to its Loan and Security Agreement with Avenue Venture Opportunities Fund II, L.P., increasing the aggregate principal outstanding to $10 million. The amendment extends the interest-only period by one year to September 30, 2027, and the maturity date by one year to September 1, 2029, while increasing the final payment fee by $200,000. Additionally, the lender's conversion right was expanded from $1 million to up to $3 million of principal, and the company issued a new warrant to purchase 1,000,000 shares at $1.00 per share, while also amending an existing warrant to reduce its exercise price from $2.32 to $1.00.

  • · The First Amendment Warrant is exercisable until June 23, 2031, and includes a beneficial ownership limitation not to exceed 19.99%.
  • · Upon a change of control, the Lender would receive shares underlying the First Amendment Warrant without payment of the exercise price.
  • · The amended Warrant's exercise price was reduced from $2.32 to $1.00 per share.
  • · The Conversion Option and Put Option may not be exercised if it would cause the Lender to exceed a beneficial ownership limitation; in such case, Pre-Funded Warrants with an exercise price of $0.0001 per share would be issued instead.
  • · The Put Option allows the company to require conversion of up to 20% of the average daily trading volume over the prior 15 trading days, provided the VWAP is at least 50% greater than the Conversion Price.
Churchill Capital Corp XI 8-K positive materiality 9/10

24-06-2026

Churchill Capital Corp XI (CCXI) announced a definitive business combination agreement with Agility Robotics, valuing the company at a pre-money equity value of $2.5B. The transaction is expected to provide over $620M in gross proceeds, including $420M from trust and ~$200M from a PIPE at $10/share, making Agility the only U.S. publicly listed pure-play humanoid company. However, the transaction is subject to shareholder approval, SEC review, and other closing conditions, with substantial redemptions a potential risk.

  • · Agility has more than 65,000 hours of operation in nine customer facilities.
  • · Digit v5 is designed to be the world's first cooperatively safe AI-enabled humanoid robot.
  • · Agility sources approximately 75% of Digit parts within the United States.
  • · Existing Agility shareholders are locked up for 180 days post-close.
  • · The investor conference call is scheduled for 8:30 a.m. ET on June 24, 2026.
Autonomix Medical, Inc. 8-K neutral materiality 2/10

24-06-2026

Autonomix Medical, Inc. filed an 8-K on June 24, 2026, reporting amendments to its articles of incorporation/bylaws (Item 5.03) and material modifications to security holder rights (Item 3.03), along with other events (Item 8.01) and exhibits (Item 9.01). No specific financial details, transaction values, or forward-looking guidance were disclosed. The filing appears to be a mandatory disclosure of corporate governance changes, but the lack of quantitative data limits assessment of materiality.

  • · Filing date: June 24, 2026
  • · AccNo: 0001437749-26-021495
  • · Size: 554 KB
  • · Items reported: 3.03, 5.03, 8.01, 9.01
Rank One Computing Corp dba ROC 8-K positive materiality 8/10

24-06-2026

Rank One Computing (ROC) announced a definitive agreement to acquire Zuccaro Technical Consulting (ZTC) for $500,000 in cash and approximately $2.5M in restricted stock, plus a performance-based earn-out and RSUs for ZTC employees. The acquisition expands ROC Evidence with digital forensics capabilities, adds active federal contracts and a specialized engineering team, and strengthens ROC's position in the $9.4B digital evidence market. However, the transaction is subject to customary closing conditions and government approvals, with expected closing in Q3 2026, and carries integration risks and dependence on federal contracts.

  • · ZTC will operate as a wholly owned subsidiary of ROC post-closing.
  • · ZTC's technology enables ingestion, processing, review, and management of large-scale digital evidence workflows including legal process returns, mobile device extractions, multimedia files, and other investigative data sources.
  • · ZTC has been operating for more than two decades with field-proven capabilities.
  • · ROC is headquartered in Denver, CO, with additional hubs in Grand Rapids, MI, and Morgantown, WV.
  • · The acquisition is expected to close in Q3 2026, subject to customary closing conditions and government approvals.
STANLEY BLACK & DECKER, INC. 8-K neutral materiality 7/10

24-06-2026

Stanley Black & Decker, Inc. entered into a $1,000,000,000 364-day credit agreement dated June 18, 2026, with Citibank as administrative agent and BofA Securities, JPMorgan Chase, and Wells Fargo Securities as lead arrangers. The facility provides a $1B unsecured revolving credit line with pricing tied to the company's credit ratings, ranging from 0.875% to 1.375% over Term SOFR or EURIBOR, and includes customary covenants and events of default. The agreement also allows for designated borrowers and includes a guarantee from the company.

  • · The credit agreement includes a $250M cap on Applicable Adjustment Addbacks per four-quarter period.
  • · Pricing grid based on credit ratings: commitment fee ranges from 0.040% to 0.150%; Term SOFR/EURIBOR margin ranges from 0.875% to 1.375%.
  • · The agreement allows for borrowings in Euros as an Alternate Currency.
  • · The facility is unsecured and includes a guarantee from the company.
  • · The agreement contains customary affirmative and negative covenants, events of default, and provisions for benchmark replacement.
Indaptus Therapeutics, Inc. 8-K neutral materiality 7/10

24-06-2026

Indaptus Therapeutics, Inc. entered into a Stock Purchase Agreement on June 17, 2026, to issue and sell 20,000,000 shares of common stock at $0.60 per share to non-U.S. accredited investors, generating approximately $12,000,000 in gross proceeds. The private placement was conducted offshore under Regulation S and Section 4(a)(2) of the Securities Act, with no commissions paid. The company must file a resale registration statement within 90 days of closing and use best efforts to have it declared effective within 75 days after filing.

  • · The shares issued represented less than 20% of the company's outstanding common stock prior to the agreement.
  • · No commissions or other compensation were paid in connection with the private placement.
  • · Each purchaser represented being a non-U.S. person under Regulation S and an accredited investor under Rule 501 of Regulation D.
  • · The registration statement for resale must be filed within 90 days of closing and declared effective within 75 days after filing (or longer if subject to SEC review).
  • · The company bears all fees and expenses related to the registration of the registrable securities.
Compass Diversified Holdings 8-K mixed materiality 7/10

24-06-2026

Compass Diversified Holdings (CODI) announced a Settlement Agreement and Plan Support Agreement in connection with the Chapter 11 proceedings of Lugano Diamonds & Jewelry Inc. The settlement is designed to accelerate the resolution of the bankruptcy, reduce ongoing costs and uncertainty, and enable more timely cash recovery for CODI. However, the settlement is subject to creditor approval and bankruptcy court confirmation, and there is no assurance that the Plan of Liquidation will be confirmed or become effective, nor as to the timing or amount of recoveries.

  • · CODI will be entitled to recoveries from the Lugano estate including proceeds from inventory disposition, tax refunds, insurance, and litigation claims pursued through a liquidation trust.
  • · In exchange for releases granted by CODI, CODI and its related parties will receive a release of claims from the Lugano estate.
  • · CODI continues to advance its previously announced review of the management services agreement, expected to complete in the coming weeks.
  • · The settlement will become effective only upon satisfaction of conditions, including effectiveness of Lugano's Plan of Liquidation.
Passage BIO, Inc. 8-K mixed materiality 9/10

24-06-2026

Passage Bio and Remix Therapeutics announced a definitive merger agreement in an all-stock transaction, with pre-merger Passage Bio shareholders expected to own approximately 7% of the combined company and pre-merger Remix stockholders approximately 93%. Concurrently, Remix secured an oversubscribed $100 million private placement financing led by Decheng Capital, expected to fund combined company operations into 2028. The combined company will operate as Remix Therapeutics under ticker RMTX, focusing on REM-422, an oral MYB mRNA degrader in Phase 1/2 trials for ACC and AML/HR-MDS. However, Passage Bio shareholders will receive non-transferable CVRs tied to uncertain pediatric gene therapy milestones, and the transaction is subject to stockholder approvals and other conditions, with closing expected in Q4 2026.

  • · Combined company to trade under ticker RMTX on Nasdaq.
  • · CVRs distributed to Passage Bio shareholders are non-transferable and not listed on any exchange.
  • · REM-422 has Orphan Drug Designation for ACC and AML and Fast Track designation for ACC.
  • · Passage Bio's lead product candidate PBFT02 targets neurodegenerative conditions including frontotemporal dementia.
  • · Transaction expected to close in Q4 2026, subject to stockholder approvals and regulatory clearances.
SPORTSMAN'S WAREHOUSE HOLDINGS, INC. 8-K neutral materiality 7/10

24-06-2026

Sportsman's Warehouse Holdings, Inc. entered into an amended and restated ABL term loan credit agreement on June 18, 2026, increasing the total facility to $45 million ($25M initial + $20M delayed draw). The agreement includes borrowing base formulas tied to credit card receivables and inventory, with advance rates that step down over time. The filing does not disclose current financial performance, so no positive or negative metrics are available.

  • · The credit agreement is an amendment and restatement of a prior $45 million ABL term loan facility originally dated June 18, 2024.
  • · The borrowing base includes eligible credit card receivables at an advance rate that when combined with the revolving facility cannot exceed 100%.
  • · Inventory advance rates are capped at 105% through April 30, 2026, then 102.5% through June 18, 2027, then 100% thereafter.
  • · The ABL Term Loan Borrowing Base is reduced by the Revolving Borrowing Base and any reserves.
  • · The agreement includes standard representations, warranties, covenants, and events of default typical for an asset-based lending facility.
CalciMedica, Inc. 8-K mixed materiality 8/10

24-06-2026

CalciMedica announced that the FDA reviewed a protocol amendment and interim safety data for its Phase 2 KOURAGE trial of Auxora in acute kidney injury (AKI) with acute hypoxemic respiratory failure, issuing no comments or questions, allowing the company to continue dosing patients. The trial was previously paused in January 2026 due to an IDMC-recommended safety concern about a mortality imbalance, but the company’s review attributed the imbalance to differences in baseline disease severity rather than drug toxicity. CalciMedica expects FDA feedback on a potential pivotal program for Auxora in acute pancreatitis in Q3 2026.

  • · The FDA’s Division of Cardiology and Nephrology Clinical Pharmacology team confirmed no comments on the submission.
  • · The KOURAGE trial was never placed on clinical hold; the enrollment pause was voluntary by the company.
  • · The comprehensive safety assessment included cause-of-death information for all deaths and an analysis of serious adverse events (SAEs).
  • · SAEs observed were consistent with prior clinical experience with Auxora and did not appear drug-related.
  • · CalciMedica expects FDA feedback on the design of a potential pivotal program for Auxora in acute pancreatitis in Q3 2026.
  • · CM5480, a proprietary oral CRAC channel inhibitor, is planned for IND clearance in mid-2027.
MERCURY GENERAL CORP 8-K neutral materiality 6/10

24-06-2026

Mercury General Corporation entered into a Second Amended and Restated Credit Agreement on June 24, 2026, amending and restating its existing $250 million revolving credit facility. The new agreement extends the maturity date and updates terms, with Bank of America as Administrative Agent. The facility is undrawn at closing, and the initial pricing is set at Level 2 based on a debt-to-capital ratio between 15% and 20%.

  • · The credit agreement includes a $250 million revolving credit facility with a maturity date extended to June 24, 2031 (5 years from closing).
  • · The facility is undrawn as of the closing date.
  • · Initial pricing is set at Pricing Level 2: commitment fee 0.125%, Term SOFR loans 1.125%, Base Rate loans 0.125%, letter of credit fee 1.000%.
  • · The agreement replaces the prior credit agreement dated as of June 24, 2021.
  • · The Borrower may request an increase in commitments up to an additional $100 million, subject to lender consent.
DuPont de Nemours, Inc. 8-K neutral materiality 6/10

24-06-2026

DuPont de Nemours, Inc. filed a Certificate of Amendment to effect a 1-for-3 reverse stock split of its common stock, effective June 24, 2026. The amendment reduces the authorized common shares from 1.67 billion to 555,555,556 and total authorized capital stock from 1.92 billion to 805,555,556. No fractional shares will be issued; holders of fractional interests will receive cash in lieu thereof.

  • · The reverse stock split was approved by the Board of Directors and stockholders in accordance with Delaware law.
  • · No fractional shares will be issued; the transfer agent will aggregate and sell fractional shares, distributing net proceeds pro rata to holders.
  • · The amendment becomes effective at 12:01 a.m. Eastern Time on June 24, 2026.
  • · All other provisions of the Certificate of Incorporation remain unchanged.
urban-gro, Inc. 8-K neutral materiality 7/10

24-06-2026

Flash Sports & Media Holdings, Inc. entered into a Securities Purchase Agreement with FirstFire Global Opportunities Fund, LLC on June 17, 2026, for the sale of a Note and related securities. The agreement includes covenants requiring the company to purchase D&O insurance within 60 days of closing and to provide irrevocable transfer agent instructions. The company also agreed to submit all claims to binding arbitration in Delaware and to pay $3,000 per day in liquidated damages if it fails to timely file an 8-K disclosing material non-public information provided to the buyer.

  • · The agreement is governed by Delaware law and all claims must be resolved through binding arbitration in Delaware.
  • · The company must purchase D&O insurance within 60 days of closing, covering officers and directors for 18 months with 2 years of tail coverage.
  • · The company must provide irrevocable transfer agent instructions and deliver corporate resolutions within 6 hours of each Note conversion.
  • · The company acknowledges that breach of transfer agent instructions could cause irreparable harm, entitling the buyer to injunctive relief.
  • · The buyer's obligation to purchase is subject to conditions including no Material Adverse Effect, no trading suspension, and delivery of good standing certificates and board resolutions.
UPEXI, INC. 8-K negative materiality 8/10

24-06-2026

Upexi, Inc. (UPXI) announced a private placement of ~$19.5 million through the issuance of 12,242,300 shares at ~$1.60 per share, executed via reduction of existing debt to an accredited investor. The company holds roughly 2.4 million SOL and focuses on a Solana-based digital asset treasury strategy, though the offering dilutes existing shareholders by over 12 million shares.

  • · No placement agent was used in the offering.
  • · The offering was made under Section 4(a)(2) of the Securities Act and/or Regulation D.
  • · Proceeds are entirely in the form of debt reduction, not new cash.
  • · Upexi describes itself as a leading Solana-focused digital asset treasury company and consumer brands owner.
  • · The company aims to acquire and hold as much Solana as possible in a disciplined and accretive fashion.
  • · Three key value accrual mechanisms: intelligent capital issuance, staking, and discounted locked token purchases.
RBC Bearings INC 8-K neutral materiality 5/10

24-06-2026

RBC Bearings entered into an amended employment agreement with CEO Dr. Michael J. Hartnett and an amendment to the employment agreement with COO Daniel A. Bergeron on June 23, 2026. The new agreements include base salary increases of 3.0% for both executives, modifications to performance-based compensation tables, and changes to equity award sizing based on average stock price. The agreements also align ROIC definitions with historical practice.

  • · Dr. Hartnett's new agreement has an initial term ending March 31, 2027, with automatic annual renewals unless 90 days' notice given.
  • · Equity awards for both executives will be sized based on RBC's average closing stock price for the six months preceding the filing of the Annual Report on Form 10-K, rather than the closing price on the award date.
  • · The agreements modify definitions regarding ROIC calculation to align with historical practice.
  • · Dr. Hartnett's performance-based cash bonus ranges from 75% to 300% of annual base salary based on Adjusted EBITDA percentage of Annual Performance Plan.
  • · Dr. Hartnett's short-term equity award ranges from 280% to 665% of annual base salary based on the same performance metric.
Absci Corp 8-K positive materiality 8/10

24-06-2026

Absci Corp announced the pricing of a $100 million underwritten offering of 13,495,277 shares at $7.41 per share, with participation from Eli Lilly & Company and leading financial institutions. The proceeds will fund the advancement of ABS-201 across androgenetic alopecia and endometriosis, as well as working capital. The offering is expected to close on June 25, 2026.

  • · The offering is being conducted under an effective shelf registration statement on Form S-3 (File No. 333-289541) filed on August 12, 2025 and effective on August 22, 2025.
  • · The offering is expected to close on or about June 25, 2026.
  • · Joint book-running managers include Jefferies, J.P. Morgan, TD Cowen, and Guggenheim Securities.
  • · ABS-201 is an AI-designed anti-PRLR antibody program targeting androgenetic alopecia and endometriosis.
Hyperscale Data, Inc. 8-K positive materiality 9/10

24-06-2026

Hyperscale Data, Inc. (GPUS-PD) announced the signing of a Master Services Agreement (MSA) with a California-based neocloud provider for 20 MW of critical AI compute capacity at its Michigan data center campus, expected to generate over $1.2 billion in revenue over a 10-year term with two five-year extension options. The agreement includes an option to expand to 52 MW, which could increase total contract value to over $3.0 billion, utilizing approximately 17% of the campus's potential 300 MW capacity. However, the deployment is subject to risks including regulatory approvals, financing, and infrastructure availability, and the company continues to operate Bitcoin mining capacity at its Montana facility while transitioning the Michigan Campus from Bitcoin mining to AI workloads.

  • · The MSA has an initial term of 10 years with two five-year extension options exercisable by the Customer.
  • · ACS is retrofitting approximately 60,000 square feet of the Michigan Campus at an estimated cost of $100M to $120M for the initial 20 MW deployment.
  • · The Company currently operates approximately 28 MW of Bitcoin mining capacity at the Michigan Campus and expects to reallocate power as AI workloads are deployed.
  • · Hyperscale Data expects to continue Bitcoin mining at its Montana facility and may maintain some mining at Michigan Campus during transition.
  • · The Company expects the divestiture of ACG to occur in the second quarter of 2027.
  • · On December 23, 2024, the Company issued 1,000,000 shares of Series F Exchangeable Preferred Stock to facilitate the divestiture.
  • · The expansion concepts for over 300 MW total power capacity remain preliminary and subject to numerous risks and uncertainties.
CubeSmart, L.P. 8-K neutral materiality 7/10

24-06-2026

CubeSmart, L.P. entered into a Third Amended and Restated Credit Agreement on June 24, 2026, replacing the existing 2022 credit facility with a new $1.0 billion revolving credit facility, including a $15 million letter of credit subfacility and a $100 million swingline subfacility. The facility is led by Wells Fargo Securities, BofA Securities, and PNC Capital Markets, with Wells Fargo Bank acting as Administrative Agent. The agreement includes financial covenants and an Applicable Margin tied to the Parent's credit rating (Level 2 on the agreement date).

  • · The agreement includes a $15 million letter of credit subfacility and a $100 million swingline subfacility.
  • · The Applicable Margin is tied to the Parent's credit rating and initially set at Level 2 as of the agreement date.
  • · The facility replaces the Second Amended and Restated Credit Agreement dated October 26, 2022.
  • · Financial covenants are defined using metrics such as Adjusted Asset Value and Adjusted EBITDA.
Wilco 63 Corp 8-K positive materiality 8/10

24-06-2026

Wilco 63 Corporation, a blank check company, priced its initial public offering of 20,000,000 units at $10.00 per unit, raising $200,000,000. The units will begin trading on Nasdaq under the symbol "WLCOU" on June 18, 2026, with the offering expected to close on June 22, 2026. The company will focus on acquiring technology-enabled businesses undergoing transformation driven by AI, automation, and robotics.

  • · Each unit consists of one Class A ordinary share and one-half of one redeemable warrant.
  • · Warrants entitle holder to purchase one Class A ordinary share at $11.50 per share, subject to adjustments.
  • · An amount equal to $10.00 per unit will be deposited into a trust account upon closing.
  • · The company has granted underwriters a 45-day option to purchase up to an additional 3,000,000 units for over-allotments.
  • · The registration statement became effective on June 17, 2026.
RESIDEO TECHNOLOGIES, INC. 8-K neutral materiality 5/10

24-06-2026

Resideo Technologies, Inc. completed an internal restructuring on June 24, 2026, merging its wholly-owned subsidiary Resideo Funding Inc. into Resideo Funding II LLC, which assumed all obligations under the company's outstanding 4.000% Senior Notes due 2029 and 6.500% Senior Notes due 2032, as well as its credit agreement. Separately, on June 22, 2026, Resideo entered into a Termination and Release Agreement with Honeywell International Inc. to terminate the Tax Matters Agreement from the 2018 spin-off, requiring a one-time cash payment of $11,600,000 to Honeywell. The restructuring is a legal entity consolidation with no change to the company's debt obligations or financial position.

  • · The merger and assumption of debt obligations were completed without requiring noteholder consent, as authorized under Section 9.01(a)(3) of the respective indentures.
  • · Resideo Funding II LLC granted a security interest in substantially all of its assets and agreed to guarantee obligations under the Credit Agreement as part of the Borrower Assumption.
  • · The Termination Agreement includes a mutual release of claims related to the Tax Matters Agreement and other tax-related liabilities from the 2018 Separation and Distribution Agreement.
Graphene & Solar Technologies Ltd 8-K neutral materiality 3/10

24-06-2026

Graphene & Solar Technologies Ltd filed an 8-K on June 24, 2026, reporting Items 1.01 (Entry into a Material Definitive Agreement), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). The filing indicates a material agreement was entered into, but no specific financial terms, counterparty details, or transaction value are disclosed. The filing is informational in nature with no quantified financial impact provided.

  • · Filing size: 5 MB, indicating exhibits may be attached but not summarized in the filing text.
  • · AccNo: 0001903596-26-000255, suggesting this is a standard SEC submission.
  • · Sector: not specified, limiting industry context.
KKR Private Equity Conglomerate LLC 8-K neutral materiality 7/10

24-06-2026

KKR Private Equity Conglomerate LLC increased its revolving credit facility by $125M to $1.225B via a joinder agreement on June 17, 2026, while also raising $280.98M through an unregistered sale of Class I, U, D, and S shares on June 1, 2026. Since inception, the company has sold approximately $10,087M of shares for cash, and the broader Private Equity K-Series Platform has raised $17,293M in total cash consideration. The filing does not disclose any negative or flat performance metrics, but the reliance on unregistered sales and the accordion feature (up to $1.5B) indicate ongoing capital needs.

  • · The credit facility matures on December 23, 2027, unless earlier terminated or accelerated upon default.
  • · The joinder includes provisions limiting undrawn commitments based on a ratio of net asset value to credit available.
  • · The share sales were exempt under Section 4(a)(2), Regulation D, and/or Regulation S of the Securities Act.
  • · The Private Equity K-Series Platform sold interests for $388M on June 1, 2026, and $17,293M since inception.
  • · The company has sold approximately $10,087M of shares for cash since inception (August 1, 2023) through the filing date.
uniQure N.V. 8-K neutral materiality 7/10

24-06-2026

uniQure N.V. announced the pricing of an upsized underwritten public offering of 4,945,055 ordinary shares at $45.50 per share, with expected gross proceeds of approximately $225 million. The offering includes a 30-day option for underwriters to purchase up to 741,758 additional shares. The offering is expected to close on June 25, 2026, subject to customary conditions.

  • · The offering is being made under an automatically effective shelf registration statement on Form S-3 (File No. 333-284168) filed on January 7, 2025.
  • · Leerink Partners, Stifel, Guggenheim Securities and RBC Capital Markets are joint bookrunning managers; H.C. Wainwright & Co. is lead manager.
  • · uniQure's pipeline includes gene therapies for Huntington's disease, refractory temporal lobe epilepsy, Fabry disease, and other severe diseases.
Consolidated Water Co. Ltd. 8-K mixed materiality 8/10

24-06-2026

On June 18, 2026, OfReg notified Consolidated Water Co. Ltd. that its board approved a new 25-year water production and distribution license for its subsidiary Cayman Water, effective August 1, 2026, ending years of negotiation uncertainty. However, the license introduces a lower rate structure that would have reduced revenues by an estimated $2.1 million in 2024, $1.9 million in 2025, and $0.6 million in Q1 2026 compared to the prior rates. The agreement provides long-term regulatory clarity but comes at a material cost to historical revenue levels.

  • · The license has a 25-year term starting August 1, 2026, with no automatic renewal; Cayman Water may apply for renewal 24-36 months before expiration.
  • · The License may be revoked by OfReg for fundamental breach, persistent non-compliance, insolvency, failure to meet demand, or other specified events.
  • · Assignment or transfer of the License requires prior written consent from OfReg.
  • · OfReg can modify the License immediately upon Cabinet direction for security, public interest, or public health reasons, with or without Cayman Water's agreement.
  • · The exchange rate for CI$ to US$ has been fixed at US$1.20 per CI$1.00 since April 1974.
  • · Statutory and regulatory fees have not yet been prescribed by Cayman Islands Parliament.
  • · The prior 1990 License expired January 31, 2018; operations continued under its terms until a new concession was granted February 18, 2025.
COLONY BANKCORP INC 8-K positive materiality 9/10

24-06-2026

Colony Bankcorp, Inc. (CBAN) announced a definitive merger agreement to acquire First Reliance Bancshares, Inc. (FSRL) in a stock-and-cash transaction valued at approximately $163 million. The combined entity will have approximately $5 billion in total assets, $4.0 billion in deposits, and $3.2 billion in loans, creating a leading Southeast community bank. The transaction is expected to close in Q4 2026, subject to regulatory and shareholder approvals, and is expected to be immediately accretive to Colony's earnings per share excluding one-time merger costs.

  • · Rick Saunders will become Executive Vice Chairman and board member of Colony post-merger.
  • · Justin Strickland will become Colony's President for South Carolina.
  • · Robert Haile will serve as Chief Investment Officer and Treasurer of Colony.
  • · Brook Moore will become Colony's Credit Officer for South Carolina.
  • · Chuck Stuart will join as Co-President of Colony Mortgage.
  • · First Reliance director Rick Redden will join the Colony Board of Directors.
  • · First Reliance Chairman Dr. Dale Lusk will have formal board observation rights.
  • · First Reliance locations in South Carolina will continue operating under the First Reliance brand.
  • · A conference call for analysts is scheduled for June 25, 2026 at 9:00 AM ET (dial-in: 1-800-715-9871, Conference ID: 3962081).
  • · Replay available until July 2, 2026 (dial-in: 1-800-770-2030, passcode: 3962081#).
  • · Investor presentation will be available on Colony's website under Investor Relations.
Beam Global 8-K neutral materiality 5/10

24-06-2026

Beam Global (BEEM) entered into a standard industrial/commercial single-tenant lease for two industrial buildings in Yuma, Arizona, totaling approximately 54,369 square feet, for use as offices, warehouse, and manufacturing of solar charging stations. The lease, dated June 16, 2026, includes an initial base rent of $7,810.25 for a partial period (July 15-31, 2026) and a security deposit of $17,581.01, with total due upon execution of $26,953.31. The full term and base rent adjustments are detailed in an addendum (Paragraphs 50-56), which is not fully disclosed in this filing.

  • · The lease is a net lease (NNN) with the lessee responsible for taxes, insurance, and maintenance.
  • · Lessor warrants that existing electrical, plumbing, fire sprinkler, lighting, HVAC, loading doors, and sump pumps are in good operating condition at start, with a 6-month warranty on HVAC and 30 days on other systems.
  • · Lessee has early possession rights prior to the commencement date, with base rent abated during early possession but other obligations (taxes, insurance, maintenance) in effect.
  • · If possession is delayed beyond 60 days after the commencement date, Lessee may cancel the lease; if delayed beyond 120 days, the lease terminates automatically unless otherwise agreed.
  • · The lease includes provisions for capital expenditure allocation between lessor and lessee for governmentally mandated improvements.
GD Culture Group Ltd 8-K negative materiality 8/10

24-06-2026

GD Culture Group Ltd (GDC) announced a registered direct offering of approximately $5.45 million, issuing 259,301,306 shares at $0.021 per share, priced at-the-market under Nasdaq rules. The offering is expected to close on June 24, 2026, with Univest Securities, LLC acting as sole placement agent. The company is undergoing a strategic transition toward AI-driven digital human technology and interactive narrative entertainment, but the significant dilution from this offering may pressure existing shareholders.

  • · The offering is being made under a shelf registration statement on Form S-3 (File No. 333-292934) filed on January 26, 2026 and effective March 18, 2026.
  • · The company is a Nevada corporation and holding company currently transitioning toward AI and virtual content generation technologies.
  • · The offering is expected to close on or about June 24, 2026, subject to customary closing conditions.
  • · A final prospectus supplement will be filed with the SEC and will be available on the SEC's website.
Gores Holdings XI, Inc. 8-K positive materiality 8/10

24-06-2026

Gores Holdings XI, Inc. announced the pricing of its initial public offering of 31,200,000 units at $10.00 per unit, raising $312 million. The units will trade on the Nasdaq Global Market under the ticker 'GHXIU' starting June 23, 2026. The offering is led by Santander as sole underwriter, with a 45-day over-allotment option for up to an additional 4,680,000 units.

  • · Each unit consists of one Class A ordinary share and one-fourth of one warrant.
  • · Each whole warrant entitles the holder to purchase one Class A ordinary share at $11.50 per share.
  • · Class A ordinary shares and warrants are expected to trade separately under symbols 'GHXI' and 'GHXIW' respectively.
  • · Santander is the sole underwriter for the offering.
  • · The registration statement was declared effective by the SEC on June 22, 2026.
  • · The company is a blank check company sponsored by an affiliate of The Gores Group.
Mind Medicine (MindMed) Inc. 8-K neutral materiality 6/10

24-06-2026

Definium Therapeutics, Inc. (Nasdaq: DFTX) announced a proposed public offering of $500 million in common shares and pre-funded warrants, with an underwriter option for an additional $75 million. The company intends to use net proceeds for R&D, potential commercialization of DT120 ODT, and working capital. However, the offering is subject to market conditions and there is no assurance of completion, size, or terms.

  • · The offering is made pursuant to a shelf registration statement on Form S-3 (File No. 333-280548) filed with the SEC on June 28, 2024.
  • · Underwriters have a 30-day option to purchase up to $75 million of common shares at the public offering price.
  • · The securities are not to be distributed in Canada or to Canadian residents.
  • · The offering is subject to market conditions and customary closing conditions; there is no assurance of completion.
PARKS AMERICA, INC 8-K positive materiality 7/10

24-06-2026

Parks America, Inc. subsidiary Aggieland-Parks, Inc. completed a $2.33 million refinancing with Cendera Bank on June 17, 2026. The 7-year term loan matures June 1, 2033, with a 25-year amortization and a balloon payment, and an initial variable rate of 6.34% (SOFR + 2.70%) that is swapped to a fixed 6.99% via an interest rate swap. The refinancing removes a $2.5 million cash collateral reserve requirement, improving liquidity, but introduces a minimum 1.20x Debt Service Coverage Ratio covenant for both the borrower and parent guarantor.

  • · The loan has a 25-year amortization schedule with a balloon payment of the outstanding principal due at maturity on June 1, 2033.
  • · The interest rate swap with SouthState Bank (ARC Fixed Rate Provider) is coterminous with the loan and designated as a cash flow hedge.
  • · The refinancing removes the $2.5 million cash collateral reserve previously required by Focus Compounding Fund, LC.
  • · Financial covenants require a minimum Debt Service Coverage Ratio of 1.20x on a trailing twelve-month basis for both the borrower and parent guarantor.
  • · The loan is secured by substantially all assets of Aggieland-Parks, Inc. and guaranteed by Parks! America, Inc.
TERADATA CORP /DE/ 8-K neutral materiality 6/10

24-06-2026

Teradata Corporation entered into a new Credit Agreement dated June 24, 2026, with Bank of America, N.A. as Administrative Agent, and a syndicate of lenders including BofA Securities, Citibank, and Wells Fargo Securities as Joint Lead Arrangers and Joint Bookrunners. The agreement refinances the existing credit facility from June 28, 2022, establishing revolving credit facilities with letter of credit and swing line subfacilities, and includes a leverage ratio covenant. No specific financial amounts or performance metrics are disclosed in this filing.

  • · The Credit Agreement includes provisions for Alternative Currencies (Sterling, Euros, Yen) and both daily rate and term rate borrowings.
  • · The agreement contains a leverage ratio covenant (Section 6.06) and allows for incremental facilities and extension of maturity date.
  • · The existing credit agreement was dated June 28, 2022, and the new agreement refinances both the revolving credit facility and term loans made thereunder.
  • · The agreement includes standard representations, warranties, affirmative and negative covenants, and events of default.
Identiv, Inc. 8-K neutral materiality 8/10

24-06-2026

Identiv, Inc. (INVE) entered into a Stock and Asset Purchase Agreement with Trackonomy Systems, Inc. on June 24, 2026, under which Buyer will purchase the Purchased Equity Interests and Purchased Assets and assume the Assumed Liabilities. Key stockholders have agreed to vote their shares in favor of the transaction and against any competing proposals, granting an irrevocable proxy to Buyer. No financial terms or monetary amounts were disclosed in this filing.

  • · The Voting and Support Agreement is dated June 24, 2026.
  • · Stockholders granted an irrevocable proxy to Buyer to vote their Covered Shares as specified in Section 1.1.
  • · The proxy is coupled with an interest and will survive the death or incapacity of each Stockholder.
  • · A Voting Exception exists if the Purchase Agreement is amended without stockholder consent in a manner that reduces consideration or is materially adverse to stockholders.
  • · Each Stockholder represents that it holds its Current Shares free and clear of all Encumbrances except as noted.
  • · No monetary consideration or per-share price is disclosed in this filing.
CEA Industries Inc. 8-K mixed materiality 8/10

24-06-2026

CEA Industries Inc. (BNC) and YZi Labs have entered into a cooperation agreement dated June 23, 2026, ending YZi Labs' consent solicitation and proxy contest. The board appointed three new directors (Ella Zhang, Alex Odagiu, Matthew Roszak) with digital asset expertise, and the company will form a CEO search committee while appointing Alex Odagiu as Interim President. The settlement adds institutional oversight and BNB ecosystem insight, but the company still faces risks related to BNB value, technology adoption, and financing for future BNB acquisitions, and remains without a permanent CEO.

  • · The annual stockholder meeting is set for July 22, 2026.
  • · The company is a 'growth-oriented company focused on managing the world's largest corporate treasury of BNB'.
  • · YZi Labs agreed to terminate its consent solicitation, withdraw books and records demands, and adhere to long-term voting commitments and standstill provisions.
  • · The board will jointly search for an additional independent director with digital assets, capital markets, and public company governance experience.
  • · David Namdar continues as CEO during the transition, reporting to the board.
  • · The cooperation agreement will be filed as an exhibit to the Form 8-K and to YZi Labs’ Schedule 13D amendment.
AMERICOLD REALTY TRUST 8-K neutral materiality 5/10

24-06-2026

Americold Realty Trust (COLD) entered into an amended and restated syndicated facility agreement on June 23, 2026, establishing a $250 million 2025 Delayed Draw Term Facility alongside revolving credit and term loan facilities. The agreement involves multiple major financial institutions as lenders and agents, including Bank of America, JPMorgan Chase, Citibank, and Royal Bank of Canada. The filing does not disclose any specific financial performance metrics or period-over-period comparisons.

  • · The agreement is dated June 23, 2026, and amends and restates the Existing Credit Agreement in its entirety (not as a novation).
  • · The facility includes multiple CUSIP numbers for different tranches: Revolving Credit Dollar Tranche (03063RBC1), Revolving Credit Alternative Currency Tranche (03063RBB3), Term A-1 Loan Facility (03063RBG2), Term A-2 Loan Facility (03063RBE7), Delayed Draw Term Facility (03063RBF4), and AUD Term Facility (03063RBD9).
  • · The agreement includes sustainability coordinators (BofA Securities, Inc. and Coöperatieve Rabobank U.A., New York Branch).
  • · The filing does not disclose any financial performance metrics, revenue, earnings, or period-over-period comparisons.
Lemonade, Inc. 8-K positive materiality 8/10

24-06-2026

Lemonade, Inc. entered into a New Business Financing Agreement with Hannover Re (Ireland) DAC on June 22, 2026, securing up to $250M in total capital to fund sales and marketing growth spend from January 1, 2027 through December 31, 2028. The agreement includes a $150M cap through 2027, a $250M cap in 2028, financing of up to 80% of monthly growth spend (max $20M per cohort), and repayment tied to a percentage of premiums collected plus a rate of return equal to the greater of 0% or the 3-year U.S. Treasury Bill rate plus 5.8%.

  • · Funding Begin Date is January 1, 2027; the agreement runs through December 31, 2028
  • · Financing is limited to 80% of monthly Growth Spend, capped at $20M per Reference Cohort per month
  • · Repayment is based on a specific percentage of premiums collected from assigned customer cohorts (Reference Premium)
  • · The Company retains all future Reference Premium after the financing is fully repaid for each Reference Cohort
  • · Interest rate is the greater of 0% or the 3-year U.S. Treasury Bill rate, plus 5.8%
  • · Standard customary representations, warranties, and covenants apply; either party can terminate the agreement per its terms
  • · The full Agreement will be filed as an exhibit to the Quarterly Report on Form 10-Q for the quarter ended June 30, 2026
Oportun Financial Corp 8-K neutral materiality 6/10

24-06-2026

Oportun Financial Corporation entered into a letter agreement with activist investor Bradley L. Radoff and his foundation on June 22, 2026, resolving board composition and governance matters. The agreement requires two current Class I directors to retire by the 2026 annual meeting, imposes a standstill restricting the Radoff Parties from exceeding 4.9% beneficial ownership or engaging in proxy solicitations through the 2028 nomination deadline, and includes mutual non-disparagement and customary standstill provisions. The agreement reflects a defensive settlement by management following activist pressure, with no financial terms disclosed.

  • · The standstill remains in effect until 11:59 p.m. PT on the day 15 days prior to the 2028 stockholder director nomination deadline, unless otherwise mutually extended in writing.
  • · During the standstill, the Radoff Parties must vote in line with the Board's recommendations on director elections/removals and other proposals, except for proposals where ISS and Glass Lewis recommendations conflict with the Board, or for extraordinary transactions.
  • · The Company agreed to reimburse the Radoff Parties for reasonable and documented out-of-pocket legal and other expenses.
Massimo Group 8-K neutral materiality 6/10

24-06-2026

Massimo Group announced it is terminating its proposed acquisition of FST Development Company Limited, which was originally disclosed in February 2026, opting instead to focus on internal development of intelligent patrol and advanced security technologies. To support this shift, the controlling shareholder is providing up to $4 million in funding. The company has made significant progress internally in AI-powered security solutions, reducing the need for the stock-based acquisition.

  • · The previously announced acquisition of FST Development Company Limited was disclosed on February 3, 2026.
  • · Massimo already has an established nationwide sales network, dealer relationships, distribution channels, operational infrastructure, and manufacturing capabilities across the United States.
  • · The company is a U.S.-based provider of utility-focused powersports vehicles, recreational products, and marine equipment.
Chemours Co 8-K mixed materiality 8/10

24-06-2026

Chemours reached a settlement with the U.S. EPA and WVDEP to resolve PFAS-related claims, agreeing to pay a $22.5 million civil penalty (of which $15 million was previously accrued) over three years and fund $90 million in mitigation projects over 15 years. The settlement provides regulatory clarity and supports the company's Pathway to Thrive strategy, but will increase environmental reserves due to expanded drinking water programs. Additionally, Chemours resolved a separate Clean Water Act lawsuit with the West Virginia Rivers Coalition for less than $1 million.

  • · The settlement covers three current operating sites: Washington Works, Fayetteville Works, and Chambers Works.
  • · The civil penalty will be paid in three annual installments in 2026, 2027, and 2028, beginning within 30 days of court approval of the Consent Decree.
  • · Mitigation projects aim to reduce PFAS emissions and enhance off-site drinking water programs, supporting a goal to reduce process emissions of fluorinated organic chemicals by 99% or more by 2030.
  • · The expansion of off-site drinking water programs in West Virginia, Ohio, and New Jersey will increase existing environmental reserves.
  • · The Consent Decree remains subject to final court approval.
  • · Chemours has approximately 5,700 employees, 28 manufacturing sites, and serves about 2,400 customers in approximately 110 countries.
Aditxt, Inc. 8-K negative materiality 10/10

24-06-2026

Aditxt, Inc. (ADTX) received a final determination from the Nasdaq Hearings Panel on June 23, 2026, denying its request to continue listing, with trading suspended effective June 25, 2026. The delisting stems from non-compliance with the Bid Price Rule (bid price below $1.00 for 30 consecutive days) and the Stockholders' Equity Requirement (stockholders' equity of -$35,174,386 vs. the $2,500,000 minimum). The Panel expressed skepticism about the company's compliance plan, noting a proposed $150 million Ignite merger and a reverse stock split plan, but highlighted that the company has completed seven reverse stock splits to date and still failed to maintain compliance.

  • · The company's stock has closed below the $1.00 minimum bid price for 50% of trading days over the past two years.
  • · Aditxt completed seven reverse stock splits to date, including one as recently as May 18, 2026, but still failed to maintain Bid Price Rule compliance.
  • · After the spinoff of Ignite, the two remaining subsidiaries (Adimune and Pearsanta) have no revenue-generating drugs or devices.
  • · The company reported a quarterly loss of approximately $5 million.
  • · The Panel noted that despite the announcement of the Ignite sale and the Dana-Farber clinical study, investor response to the stock price was not favorable.
  • · The company may request a review by the Nasdaq Listing and Hearing Review Council within 15 days of the Notice (by approximately July 8, 2026).
WEYCO GROUP INC 8-K neutral materiality 6/10

24-06-2026

Weyco Group, Inc. announced the termination of its defined benefit pension plan effective August 31, 2026, subject to PBGC review. The plan is overfunded as of December 31, 2025, so no additional cash contributions are expected. Approximately 400 participants are impacted, but their accrued benefits remain unchanged.

  • · The plan was overfunded as of December 31, 2025, so no additional cash contributions are expected upon termination.
  • · The termination is subject to review by the Pension Benefit Guaranty Corporation under standard termination procedures.
  • · The Company retains the right to change the effective date or revoke the termination decision, but currently has no intent to do so.
Exeter Automobile Receivables Trust 2026-3 8-K neutral materiality 7/10

24-06-2026

Exeter Automobile Receivables Trust 2026-3 completed a $1.292 billion asset-backed securitization on June 24, 2026, issuing eight classes of notes secured by sub-prime auto loans. The transaction involves the transfer of receivables from EFCAR to the trust and ultimately to Exeter Holdings Trust 2026-3, with Citibank as indenture trustee. The notes range from Class A-1 (4.046% coupon) to Class E (7.42%) and Class N (6.66%), reflecting varying credit risk.

  • · The transaction closed on June 24, 2026, with agreements dated as of May 31, 2026.
  • · The notes are secured by sub-prime automobile loan contracts.
  • · The indenture trustee is Citibank, N.A.
  • · The backup servicer is Citibank, N.A.
  • · The asset representations reviewer is Clayton Fixed Income Services LLC.
  • · The lockbox bank is Wells Fargo Bank, National Association.
  • · The underwriting agreement was previously filed on June 18, 2026.
  • · The filing includes exhibits for the indenture, trust agreements, sale and servicing agreement, purchase agreement, contribution agreement, asset representations review agreement, custodian agreement, and accession agreement.
Ford Credit Auto Owner Trust 2026-B 8-K neutral materiality 3/10

24-06-2026

Ford Credit Auto Owner Trust 2026-B filed an 8-K on June 24, 2026, reporting the entry into material definitive agreements in connection with the issuance of asset-backed securities (Notes) as described in the Prospectus dated June 16, 2026. The filing includes multiple transaction documents dated June 1, 2026, such as an Indenture, Trust Agreement, and Sale and Servicing Agreement. No financial results or period-over-period comparisons were provided in this filing.

  • · Filing is an 8-K, Items 1.01 and 9.01, related to entry into material definitive agreements.
  • · Transaction documents include Indenture, Trust Agreement, Receivables Purchase Agreement, Sale and Servicing Agreement, Administration Agreement, Account Control Agreement, and Asset Representations Review Agreement.
  • · All agreements are dated as of June 1, 2026.
  • · Prospectus was filed under Rule 424(b)(2) on June 16, 2026.
  • · Depositor is Ford Credit Auto Receivables Two LLC, sponsor is Ford Motor Credit Company LLC.
  • · Trust is Ford Credit Auto Owner Trust 2026-B.
  • · The Bank of New York Mellon serves as Indenture Trustee; U.S. Bank Trust National Association serves as Owner Trustee.
  • · Clayton Fixed Income Services LLC serves as Asset Representations Reviewer.
  • · No financial statements or numerical data were included in this filing.
Chewy, Inc. 8-K neutral materiality 7/10

24-06-2026

Chewy, Inc. entered into a $600.0 million Initial Term Loan credit agreement on June 23, 2026, with JPMorgan Chase Bank, N.A. as administrative and collateral agent, and a syndicate of lead arrangers including Wells Fargo, Citigroup, Morgan Stanley, BofA Securities, RBC Capital Markets, and Barclays. The filing also references an existing ABL Credit Agreement (dated June 18, 2019, as amended) and includes detailed covenants, conditions, and events of default. No financial performance metrics or period-over-period comparisons are provided in this filing.

  • · The credit agreement includes provisions for joint and several liability among the Initial Borrower and any Co-Borrowers.
  • · The agreement references an ABL Intercreditor Agreement dated June 23, 2026, among the Collateral Agent, Wells Fargo Bank, and other parties.
  • · The filing includes detailed negative covenants limiting incurrence of indebtedness, liens, fundamental changes, asset sales, and restricted payments.
  • · The agreement contains standard events of default and provisions for application of proceeds upon default.
  • · The filing does not disclose any financial performance data, revenue, or profitability metrics.
Wells Fargo Commercial Mortgage Trust 2026-5C9 8-K neutral materiality 5/10

24-06-2026

Wells Fargo Commercial Mortgage Securities, Inc. filed an 8-K on June 24, 2026, reporting the issuance of $1.5B in commercial mortgage pass-through certificates (Series 2026-5C9) backed by 29 fixed-rate mortgage loans and subordinate interests in two additional loans secured by 138 commercial properties. The filing also discloses that the ONX Industrial Campus Whole Loan, which includes one of the trust's mortgage loans, was transferred to a separate securitization (BBCMS 2026-5C42) effective June 24, 2026, with servicing terms substantially similar to the original agreement. No financial performance data is provided in this filing.

  • · The ONX Industrial Campus Whole Loan includes six additional pari passu promissory notes not held by the issuing entity.
  • · The BBCMS 2026-5C42 Pooling and Servicing Agreement is dated June 1, 2026, and was attached as Exhibit 4.1.
  • · The trust was formed on May 28, 2026 under New York law.
  • · The certificates were issued under a Pooling and Servicing Agreement dated May 1, 2026.
  • · The prospectus for the certificates was filed under Rule 424(b)(2) on May 12, 2026 (SEC File Number 333-282099-13).

Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 50 filings

$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.

More from: US Corporate Distress Financial Stress SEC Filings

🇺🇸 More from United States

View all →